Breakthrough in MASH Treatment: Organovo's FXR314 Shows Promising Phase 2 Results In a significant step forward for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Organovo Holdings Inc. has announced positive Phase 2 trial results for its experimental drug, FXR314. This development marks a pivotal moment in the fight against MASH, a severe form of fatty liver disease that poses a su...
水涨船高 : 对于明天的股价有什么想法
Jaguar8楼主 水涨船高: It will drop